Effect of ribociclib Plus fulvestrant on overall survival in the treatment of advanced breast cancer - updated MONALEESA-3 results

被引：0

作者：

Dubianski, Roman ^{[1
]}

机构：

[1] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Breast Canc & Reconstruct Surg, WK Roentgena 5 St, PL-02781 Warsaw, Poland

来源：

ONCOLOGY IN CLINICAL PRACTICE | 2022年 / 18卷 / 03期

关键词：

breast cancer; ribociclib; fulvestrant; CDK4/6; inhibitor; PHASE-I; TRIAL; THERAPY;

D O I：

10.5603/OCP.2021.0034

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The results of the treatment of ER-positive/HER2-negative advanced breast cancer have been improved in the last few years due to the use of CDK4/6 inhibitors combined with endocrine therapy. Ribociclib with fulvestrant significantly prolonged progression-free survival and overall survival in the phase-III MONALEESA-3 trial. The newest update of the trial (after 56.3 months of observation) showed significant improvement in overall survival in the experimental arm for more than ayear: mOS was 53.7 months in the ribociclib plus fulvestrant arm and 41.5 months in the placebo plus fulvestrant arm (risk reduction of 27%). Subgroup analysis confirmed the efficacy of the treatment in both the first and second lines of treatment. The study also showed that adding ribociclib to the endocrine treatment prolongs the median time to chemotherapy. No new toxicities were observed in longer observation.

引用

页码：189 / 194

页数：6

共 50 条

[21] Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3
Slamon, Dennis J.
Neven, Patrick
Chia, Stephen
Fasching, Peter A.
De Laurentiis, Michelino
Im, Seock-Ah
Petrakova, Katarina
Bianchi, Giulia Val
Esteva, Francisco J.
Martin, Miguel
Nusch, Arnd
Sonke, Gabe S.
De la Cruz-Merino, Luis
Beck, J. Thaddeus
Pivot, Xavier
Vidam, Gena
Wang, Yingbo
Lorenc, Karen Rodriguez
Miller, Michelle
Taran, Tetiana
Jerusalem, Guy
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (24) : 2465 - +
[22] Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer
Tolaney, Sara M.
Im, Young-Hyuck
Calvo, Emiliano
Lu, Yen-Shen
Hamilton, Erika
Forero-Torres, Andres
Bachelot, Thomas
Maur, Michela
Fasolo, Angelica
Tiedt, Ralph
Nardi, Lisa
Stammberger, Uz
Abdelhady, Ahmed M.
Ruan, Shiling
Lee, Soo Chin
CLINICAL CANCER RESEARCH, 2021, 27 (02) : 418 - 428
[23] Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer
Mehta, Rita S.
Barlow, William E.
Albain, Kathy S.
Vandenberg, Ted A.
Dakhil, Shaker R.
Tirumali, Nagendra R.
Lew, Danika L.
Hayes, Daniel F.
Gralow, Julie R.
Linden, Hannah H.
Livingston, Robert B.
Hortobagyi, Gabriel N.
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (13): : 1226 - 1234
[24] Ribociclib (RIB) plus fulvestrant (FUL) in hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-3 biomarker analyses
Neven, P.
Petrakova, K.
Bianchi, G. V.
Merino, L. De la Cruz
Jerusalem, G.
Beck, J. T.
Sonke, G. S.
Chia, S.
Brucker, S.
Wang, Y.
He, W.
Lorenc, K. Rodriguez
Su, F.
Im, S-A.
ANNALS OF ONCOLOGY, 2018, 29 : 113 - +
[25] Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
Colombo, Giorgio Lorenzo
Valentino, Maria Chiara
Fabi, Alessandra
Dieci, Maria Vittoria
Caruggi, Mauro
Bruno, Giacomo Matteo
Lombardi, Gloria
Di Matteo, Sergio
THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2023, 19 : 301 - 312
[26] Association of quality of life (QOL) with overall survival (OS) in patients (pts) with HR+/HER2-advanced breast cancer (ABC) treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA-3 (ML-3) and ML-7 trials
Fasching, P. A.
Harbeck, N.
Jerusalem, G.
Colleoni, M. A.
Neven, P.
Franke, F.
De laurentiis, M.
Tripathy, D.
Martin, M.
Babu, G.
Yardley, D.
Wheatley-Price, P.
Chan, A.
Vazquez, R. Villanueva
Nusch, A.
Gu, E.
Hu, H.
Pathak, P.
Thuerigen, A.
Bardia, A.
ANNALS OF ONCOLOGY, 2021, 32 : S460 - S460
[27] Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib (RIB) plus fulvestrant (FUL) as first-line (1L) and second-line (2L) therapy in MONALEESA-3 (ML-3)
Fasching, P.
Neven, P.
Jerusalem, G.
Beck, J. T.
Chan, A.
De Laurentiis, M.
Bianchi, G. V.
Martin Jimenez, M.
Chia, S.
Gaur, A.
Sondhi, M.
Rodriguez-Lorenc, K.
Lanoue, B.
Chandiwana, D.
Nusch, A.
ANNALS OF ONCOLOGY, 2020, 31 : S67 - S68
[28] Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer
Slamon, Dennis J.
Dieras, Veronique
Rugo, Hope S.
Harbeck, Nadia
Im, Seock-Ah
Gelmon, Karen A.
Lipatov, Oleg N.
Walshe, Janice M.
Martin, Miguel
Chavez-MacGregor, Mariana
Bananis, Eustratios
Gauthier, Eric
Lu, Dongrui R.
Kim, Sindy
Finn, Richard S.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (09) : 994 - 1000
[29] Correlative analysis of overall survival by intrinsic subtype across the MONALEESA-2,-3, and-7 studies of ribociclib plus endocrine therapy in patients with HR+/HER2-advanced breast cancer
Carey, Lisa
Solovieff, Nadia
Andre, Fabrice
O'Shaughnessy, Joyce
Cameron, David A.
Janni, Wolfgang
Sonke, Gabe S.
Yap, Yoon-Sim
Yardley, Denise A.
Zarate, Juan Pablo
Taran, Tetiana
Su, Faye
Lteif, Agnes
Prat, Aleix
CANCER RESEARCH, 2022, 82 (04)
[30] Ribociclib plus fulvestrant in postmenopausal women with HR+, HER2-advanced breast cancer (ABC)
Tolaney, S. M.
Forero-Torres, A.
Boni, V.
Bachelot, T.
Lu, Y-S
Maur, M.
Fasolo, A.
Motta, M.
Pan, C.
Dobson, J.
Hewes, B.
Lee, S. Chin
CANCER RESEARCH, 2017, 77

← 1 2 3 4 5 →